Prevalence of depression in adults with cancer: A systematic review

Psychological Medicine Research Department of Psychiatry, University of Oxford, Oxford.
Annals of Oncology (Impact Factor: 7.04). 11/2012; 24(4). DOI: 10.1093/annonc/mds575
Source: PubMed


Depression has substantial effects on cancer patients' quality of life. Estimates of its prevalence vary widely. We aimed to systematically review published studies to obtain the best estimate of the prevalence of depression in clinically meaningful subgroups of cancer patients.DesignSystematic review that addressed the limitations of previous reviews by (i) including only studies that used diagnostic interviews; (ii) including only studies that met basic quality criteria (random or consecutive sampling, ≥70% response rate, clear definition of depression caseness, sample size ≥100); (iii) grouping studies into clinically meaningful subgroups; (iv) describing the effect on prevalence estimates of different methods of diagnosing depression.ResultsOf 66 relevant studies, only 15 (23%) met quality criteria. The estimated prevalence of depression in the defined subgroups was as follows: 5% to 16% in outpatients, 4% to 14% in inpatients, 4% to 11% in mixed outpatient and inpatient samples and 7% to 49% in palliative care. Studies which used expert interviewers (psychiatrists or clinical psychologists) reported lower prevalence estimates.Conclusions
Of the large number of relevant studies, few met our inclusion criteria, and prevalence estimates are consequently imprecise. We propose that future studies should be designed to meet basic quality criteria and employ expert interviewers.

13 Reads
  • Source
    • "Σε αυτές επισημαίνεται ότι η εντατική φροντίδα είναι πιο αποτελεσματική από την πρότυπη φροντίδα στη μείωση των καταθλιπτικών συμπτωμάτων. Ενώ φαίνεται λογικό να θεραπεύεται η κατάθλιψη σε άτομα με καρκίνο του πνεύμονα με τις πρότυπες θεραπείες έως ότου γίνουν διαθέσιμες πιο συγκεκριμένες ενδείξεις, οι κλινικοί γιατροί πρέπει να γνωρίζουν ότι η αποτελεσματικότητα και οι πιθανές δυσμενείς επιπτώσεις από αυτές τις θεραπείες παραμένουν άγνωστες σε αυτούς τους ασθενείς (Walker et al., 2013). ΣΥΜΠΕΡΑΣΜΑΤΑ Ο καρκίνος του πνεύμονα είναι η δεύτερη συχνότερη μορφή καρκίνου και η κύρια αιτία θανάτου από καρκίνο και στα δύο φύλα. "
    [Show description] [Hide description]
    DESCRIPTION: Ανασκόπηση της βιβλιογραφίας σχετικά με την ψυχική υγεία ασθενών με καρκίνο πνεύμονα.
  • Source
    • "Depression is a primary cause of disability and functional limitations [2], reduced quality of life [3], and mortality [4]. Depression is also associated with a number of physical conditions, such as cancer, cardiovascular diseases and diabetes, among others [5] [6] [7]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objectives This paper aims to systematically review observational studies that have analysed whether depressive symptoms in the community are associated with higher general hospital admissions, longer hospital stays and increased risk of re-admission. Methods We identified prospective studies that looked at depressive symptoms in the community as a risk factor for non-psychiatric general hospital admissions, length of stay or risk of re-admission. The search was carried out on MEDLINE, PsycINFO, Cochrane Library Database, and followed up with contact with authors and scanning of reference lists. Results Eleven studies fulfilled our inclusion and exclusion criteria, and all were deemed to be of moderate to high quality. Meta-analysis of seven studies with relevant data suggested that depressive symptoms may be a predictor of subsequent admission to a general hospital in unadjusted analyses (RR = 1.36, 95% CI: 1.28–1.44), but findings after adjustment for confounding variables were inconsistent. The narrative synthesis also reported depressive symptoms to be independently associated with longer length of stay, and higher re-admission risk. Conclusions Depressive symptoms are associated with a higher risk of hospitalisation, longer length of stay and a higher re-admission risk. Some of these associations may be mediated by other factors, and should be explored in more details.
    Journal of psychosomatic research 11/2014; DOI:10.1016/j.jpsychores.2014.11.002 · 2.74 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Depression is a leading cause of disease burden worldwide and is especially problematic in people with chronic diseases, including cancer. Although depression can be effectively treated in the general population using antidepressant medication and psychological treatments, these treatments may have different benefits and harms in cancer patients. Previous reviews have not adequately addressed this topic. We therefore aimed to determine which, if any, treatments are effective for patients with diagnoses of both cancer and depression. Method: We conducted a systematic review of relevant randomized controlled trials identified through searches of Medline, EMBASE, PsycINFO and The Cochrane Central Register of Controlled Trials (CENTRAL). Results: Seven relatively small trials met the selection criteria. These provided some evidence that antidepressant medication, given alone or in combination with a psychological treatment, may be effective. We found no good evidence for psychological treatments given alone or for any other forms of treatment. Conclusions: There is very limited evidence from clinical trials to guide the treatment of cancer patients with a diagnosis of depression, especially for psychological treatments. High quality trials of treatments for depression in patients with cancer are urgently needed.
    Psychological Medicine 06/2013; 44(5):1-11. DOI:10.1017/S0033291713001372 · 5.94 Impact Factor
Show more